TP53 and cancer: While earlier studies have demonstrated TE derepression by few combinations of epigenetic drugs in individual cancer types15,17,18,21,50, a comprehensive understanding of the mechanisms of TE activation across different cancer types—especially in the context of p53 activity, has remained elusive.